0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

      research-article
      1 , 2 , 2 , 3 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , , 2
      RMD Open
      BMJ Publishing Group
      biological therapy, systemic vasculitis, autoimmune diseases, certolizumab pegol

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).

          Methods

          Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.

          Results

          We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet’s disease (n=10), psoriatic arthritis (n=8), Crohn’s disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),

          Conclusions

          CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop

          To begin a process of standardizing the methods for reporting clinical data in the field of uveitis. Consensus workshop. Members of an international working group were surveyed about diagnostic terminology, inflammation grading schema, and outcome measures, and the results used to develop a series of proposals to better standardize the use of these entities. Small groups employed nominal group techniques to achieve consensus on several of these issues. The group affirmed that an anatomic classification of uveitis should be used as a framework for subsequent work on diagnostic criteria for specific uveitic syndromes, and that the classification of uveitis entities should be on the basis of the location of the inflammation and not on the presence of structural complications. Issues regarding the use of the terms "intermediate uveitis," "pars planitis," "panuveitis," and descriptors of the onset and course of the uveitis were addressed. The following were adopted: standardized grading schema for anterior chamber cells, anterior chamber flare, and for vitreous haze; standardized methods of recording structural complications of uveitis; standardized definitions of outcomes, including "inactive" inflammation, "improvement'; and "worsening" of the inflammation, and "corticosteroid sparing," and standardized guidelines for reporting visual acuity outcomes. A process of standardizing the approach to reporting clinical data in uveitis research has begun, and several terms have been standardized.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Behçet's disease.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease.

                Bookmark

                Author and article information

                Journal
                RMD Open
                RMD Open
                rmdopen
                rmdopen
                RMD Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2056-5933
                2022
                6 December 2022
                : 8
                : 2
                : e002693
                Affiliations
                [1 ]departmentRheumatology , Hospital Comarcal de Laredo , Laredo, Spain
                [2 ]departmentRheumatology , Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander, Spain
                [3 ]departmentOphthalmology , Hospital Clinic de Barcelona , Barcelona, Spain
                [4 ]departmentRheumatology , University Hospital Complex Badajoz , Badajoz, Spain
                [5 ]departmentRheumatology , Hospital del Mar , Barcelona, Spain
                [6 ]departmentRheumatology , Joan XXIII University Hospital in Tarragona , Tarragona, Spain
                [7 ]departmentInternal Medicine , Complejo Hospitalario de Navarra , Pamplona, Spain
                [8 ]departmentRheumatology , Hospital Universitario del Tajo , Aranjuez, Spain
                [9 ]departmentRheumatology , Hospital de Basurto , Basurto, Spain
                [10 ]departmentOphthalmology , Complejo Asistencial Universitario de Leon , Leon, Spain
                [11 ]departmentDepartment of Rheumatology , Araba University Hospital , Vitoria-Gasteiz, Spain
                [12 ]departmentRheumatology , Hospital Universitario de Toledo , Toledo, Spain
                [13 ]departmentOphthalmology , General University Hospital Consortium of Valencia , Valencia, Spain
                [14 ]departmentRheumatology , University Hospital Lucus Augusti , Lugo, Spain
                [15 ]departmentRheumatology , Complejo Asistencial de Palencia , Palencia, Spain
                [16 ]departmentRheumatology , Hospital of Donostia , San Sebastian, Spain
                [17 ]departmentRheumatology , Hospital Universitario de Mostoles , Mostoles, Spain
                [18 ]departmentRheumatology , Hospital Virgen de Valme , Sevilla, Spain
                [19 ]departmentRheumatology , Hospital Can Misses , Eivissa, Illes Balears, Spain
                [20 ]departmentRheumatology , Hospital de Merida , Merida, Spain
                [21 ]departmentRheumatology , Hospital General Universitari de Castello , Castellon de la Plana, Spain
                [22 ]departmentRheumatology , Hospital Universitario San Juan de Alicante , Sant Joan d'Alacant, Spain
                [23 ]departmentRheumatology , Hospital General Universitario de Alicante , Alicante, Spain
                [24 ]departmentOphthalmology , Hospital General Universitario de Alicante , Alicante, Spain
                [25 ]departmentRheumatology , Hospital Universitario de Salamanca , Salamanca, Spain
                [26 ]departmentRheumatology , Hospital de la Santa Creu i Sant Pau , Barcelona, Spain
                [27 ]departmentRheumatology , Complejo Hospitalario Universitario de Pontevedra , Pontevedra, Spain
                [28 ]departmentRheumatology , Fundació Hospital de l'Esperit Sant , Barcelona, Spain
                [29 ]departmentPediatric , Hospital Universitario 12 de Octubre , Madrid, Spain
                [30 ]departmentRheumatology , Hospital de Sagunto , Sagunto, Spain
                [31 ]departmentOphthalmology , Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander, Spain
                [32 ]departmentInternal Medicine , Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander, Spain
                [33 ]departmentMedicine and Psychiatry Department , Universidad de Cantabria , Santander, Spain
                Author notes
                [Correspondence to ] Dr José L Hernández; hernandezjluis@ 123456gmail.com

                JLH and RB are joint senior authors.

                Author information
                http://orcid.org/0000-0001-6147-6633
                http://orcid.org/0000-0001-8070-6916
                http://orcid.org/0000-0002-0910-4944
                http://orcid.org/0000-0002-6585-8847
                http://orcid.org/0000-0003-2344-2285
                Article
                rmdopen-2022-002693
                10.1136/rmdopen-2022-002693
                9730404
                36597972
                3b199c74-7c39-48ef-a5c2-8b3088af4ec9
                © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 25 August 2022
                : 31 October 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004587, Instituto de Salud Carlos III;
                Categories
                Miscellaneous
                1506
                Original research
                Custom metadata
                unlocked
                free

                biological therapy,systemic vasculitis,autoimmune diseases,certolizumab pegol

                Comments

                Comment on this article